Syndax Announces Participation in November Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) announced its participation in four major healthcare investor conferences in November 2024. The company's CEO Michael A. Metzger and management team will attend: Guggenheim's Inaugural Healthcare Innovation Conference in Boston (Nov 13), UBS Global Healthcare Conference in Ranchos Palos Verdes (Nov 14), Stifel 2024 Healthcare Conference in New York (Nov 18), and Jefferies London Healthcare Conference (Nov 20-21). Live webcasts of the fireside chats will be available on the company's website.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +0.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Guggenheim's Inaugural Healthcare Innovation Conference in
Boston, MA with a fireside chat on Wednesday, November 13, 2024, at 1:30 p.m. ET - UBS Global Healthcare Conference in Ranchos Palos Verdes, CA with a fireside chat on Thursday, November 14, 2024, at 10:15 a.m. ET / 7:15 a.m. PT
- Stifel 2024 Healthcare Conference in
New York, NY with a fireside chat on Monday, November 18, 2024, at 1:50 p.m. ET - Jefferies London Healthcare Conference in
London, UK , November 20-21, 2024
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-in-november-investor-conferences-302293915.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.